Morgan Stanley’s Psyence Biomedical PBM Stock Holding History

Morgan Stanley’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$116K	Buy	+37,804	New	+$172K	﹤0.01%	6194
2025 Q2	–	Sell	-1	Closed	-$41	–	8293
2025 Q1	$41	Buy	+1	New	+$64	﹤0.01%	7790
2024 Q4	–	Sell	-13	Closed	-$4.84K	–	8115
2024 Q3	$4.84K	Buy	13 +8	+160%	+$10.8K	﹤0.01%	6925
2024 Q2	$6K	Buy	+5	New	+$15K	﹤0.01%	6808

Other funds holding PBM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.93B AUM 16.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Caitlin John Brighton, Michigan $183M AUM 30.77% 1-Year Est. Return

Morgan Stanley's PBM Position: Q2 2026 in Review

Morgan Stanley opened a new position in Psyence Biomedical (PBM) in Q2 2026: 37,804 shares worth $116K. The stake represents ﹤0.01% of the portfolio and ranks #6194 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in PBM as recently as Q1 2025.

Morgan Stanley first reported a position in PBM in Q2 2024 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold PBM as of Q2 2026.

Morgan Stanley held 37,804 shares of Psyence Biomedical worth $116K as of Q2 2026.
Psyence Biomedical was a new Morgan Stanley position in Q2 2026.
Psyence Biomedical made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6194 holding.
Morgan Stanley first reported a position in Psyence Biomedical in Q2 2024 and has held it in 4 quarters since.
9 funds tracked by Wall St. Rank held Psyence Biomedical as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.